Published in Br J Cancer on December 13, 2004
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 2.25
Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J (2010) 1.51
Residual nodal disease in biopsy proven n1/n2 breast cancer following neoadjuvant systemic therapy. World J Surg (2010) 1.37
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer (2012) 1.18
Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg (2009) 1.16
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer (2010) 1.05
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia (2010) 1.04
EPMA position paper in cancer: current overview and future perspectives. EPMA J (2015) 1.04
The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer (2008) 1.02
Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol (2011) 0.97
Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer (2012) 0.96
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol (2013) 0.96
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol (2012) 0.94
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer (2006) 0.89
Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. Int Semin Surg Oncol (2006) 0.89
Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor. PLoS One (2013) 0.88
Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer. Oncol Lett (2014) 0.86
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer (2010) 0.86
Advantage of sentinel lymph node biopsy before neoadjuvant chemotherapy in breast cancer treatment. Surg Today (2009) 0.85
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy. J Oncol (2013) 0.84
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer (2007) 0.84
Discordance of Estrogen & Progesterone Receptors After Neoadjuvant Chemotherapy in Breast Cancer- an Indian Study. Indian J Surg Oncol (2016) 0.83
Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. Breast Cancer Res (2007) 0.83
The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Mod Pathol (2012) 0.83
Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials. PLoS One (2015) 0.82
Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. J Breast Cancer (2014) 0.80
Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of care. BMC Cancer (2007) 0.80
Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer (2016) 0.80
Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. Exp Ther Med (2011) 0.79
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. Cancer Res Treat (2014) 0.79
Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nat Rev Clin Oncol (2016) 0.78
Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? World J Surg (2016) 0.77
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat (2008) 0.76
Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer. Exp Ther Med (2015) 0.76
Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. EBioMedicine (2016) 0.75
A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character. Springerplus (2013) 0.75
Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer. Medicine (Baltimore) (2015) 0.75
Pre-operative systemic therapy in locally advanced breast cancer: a single institution experience. Ecancermedicalscience (2009) 0.75
Designing adjuvant treatment based on biological measurements in the neoadjuvant setting. Breast Cancer Res (2010) 0.75
A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. Oncotarget (2016) 0.75
Allelic imbalance at the HER2/TOP2A locus in breast cancer. Diagn Pathol (2015) 0.75
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl (2013) 0.75
Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study. Croat Med J (2016) 0.75
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Invest New Drugs (2010) 0.75
Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging. J Med Imaging (Bellingham) (2017) 0.75
Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am (2018) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 12.78
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol (1998) 9.32
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY. Ann Surg (1943) 6.42
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol (2001) 5.28
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol (1998) 2.59
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst (1990) 2.25
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer (2002) 2.18
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol (1995) 1.87
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg (2002) 1.71
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer (1994) 1.60
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol (1991) 1.39
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer (1996) 1.39
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol (1999) 1.25
Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol (2003) 1.24
Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol (1998) 1.09
Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol (2003) 1.02
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol (2000) 0.98
Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol (2001) 0.92
Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. Int J Cancer (1999) 0.89
Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study. Cancer (1989) 0.84
In vitro adriamycin sensitivity test and hormonal receptors in primary breast cancer. Eur J Cancer (1980) 0.82
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft. Nature (1976) 2.77
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Can magnetic-resonance imaging help elucidate natural history of breast cancer multicentricity? Lancet (1998) 2.70
The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys (1994) 2.65
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet (1998) 2.27
A comparison of children affected by prenatal alcohol exposure and attention deficit, hyperactivity disorder. Alcohol Clin Exp Res (1997) 2.13
A colony-forming assay for human tumour xenografts using agar in diffusion chambers. Br J Cancer (1976) 2.11
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology (2006) 1.98
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol (2003) 1.92
Metaplastic breast carcinomas are basal-like tumours. Histopathology (2006) 1.80
A high incidence of vertebral fracture in women with breast cancer. Br J Cancer (1999) 1.74
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Palliative chemotherapy for advanced non-small cell lung cancer. BMJ (1994) 1.67
Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol (1991) 1.66
Comparative genomic hybridization reveals extensive variation among different MCF-7 cell stocks. Cancer Genet Cytogenet (2000) 1.65
Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ (1992) 1.63
CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer (2001) 1.62
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol (2001) 1.61
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58
Surgical experience and supervision may influence the quality of lower limb amputation. Ann R Coll Surg Engl (2002) 1.57
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol (2006) 1.57
Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol (1995) 1.57
Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol (2003) 1.55
Short-term results of femoropopliteal subintimal angioplasty. Br J Surg (2000) 1.54
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Ann Oncol (1999) 1.51
Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol (1987) 1.51
Breast cancer in adolescents and young women. Eur J Cancer (2003) 1.49
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
Evaluation of a nurse-led telephone clinic in the follow-up of patients with malignant glioma. Clin Oncol (R Coll Radiol) (2000) 1.49
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer (2005) 1.48
Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol. Br J Cancer (1998) 1.48
Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer (2006) 1.48
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet (1995) 1.47
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br J Cancer (1978) 1.46
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene (2010) 1.45
British Dietetic Association evidence-based guidelines for the dietary management of Crohn's disease in adults. J Hum Nutr Diet (2013) 1.44
The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer (1998) 1.44
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer (2009) 1.44
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer (2004) 1.43
Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol (R Coll Radiol) (2008) 1.43
Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol (2003) 1.43
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab (1993) 1.41
New treatments for advanced cancer: an approach to prioritization. Br J Cancer (2000) 1.41
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
Descriptive study comparing routine hospital administrative data with the Vascular Society of Great Britain and Ireland's National Vascular Database. Eur J Vasc Endovasc Surg (2006) 1.39
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat (1998) 1.39
Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC). Clin Oncol (R Coll Radiol) (2001) 1.39
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet (1980) 1.38
Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone (1996) 1.38
Effects of prenatal alcohol exposure at school age. I. Physical and cognitive development. Neurotoxicol Teratol (1991) 1.37
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol (1984) 1.34
Differences among Asian patients. Br Med J (Clin Res Ed) (1986) 1.34
Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res (1998) 1.33
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) (1981) 1.33
Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer (1995) 1.33
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res (1999) 1.32
Microcirculation of the islets of Langerhans. Long Beach Veterans Administration Regional Medical Education Center Symposium. Diabetes (1996) 1.32
Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet (1997) 1.31
In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice. Cancer Res (1978) 1.31
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer (1995) 1.29
Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet (1978) 1.27
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed (1998) 1.27
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab (1982) 1.25
Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.25
Demystifying basal-like breast carcinomas. J Clin Pathol (2007) 1.22
24-hour survival of autotransfused red cells in elective aortic surgery: a comparison of two intraoperative autotransfusion systems. Br J Surg (1991) 1.22
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer (1993) 1.22
Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer (1989) 1.20
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer (1979) 1.19
The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas. Oncogene (1996) 1.19
Health-related quality of life in narcolepsy. J Sleep Res (2001) 1.18
Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst (1998) 1.18
The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf) (1993) 1.18
Factors associated with emotional and behavioural problems among school age children of breast cancer patients. Br J Cancer (2006) 1.18
In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer. Lancet (1989) 1.18
Effects of prenatal alcohol exposure at school age. II. Attention and behavior. Neurotoxicol Teratol (1991) 1.18
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer (2003) 1.18
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. Br J Cancer (2007) 1.18
Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab (2004) 1.17